Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONKO-005: Adjuvant therapy of R0-resected pancreatic cancer with gemcitabine plus erlotinib
2007-003813-15Phase 3Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of erlotinib and gemcitabine in pancreatic cancer (PC) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Disease-free survival and Overall survival. Started Oct 2007; status: completed.
02
Drugs
erlotinibgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2007-003813-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003813-15.